|
Title
|
|
|
|
Trifluridine/tipiracil : an emerging strategy for the management of gastrointestinal cancers
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Fluoropyrimidines are currently the backbone of treatment for gastrointestinal (GI) cancers but development of resistance to these agents remains a major problem. Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer. This article reviews the clinical value of trifluridine/tipiracil as a monotherapy, including recent trials in GI cancers, and the potential benefit of combining it with other agents in patients with GI cancers, including the preclinical rationale for combination therapy and recently completed and ongoing clinical trials. Data gathered so far suggest that trifluridine/tipiracil has the potential to form the chemotherapeutic backbone in the continuum of care for GI cancers in the future. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Future oncology
|
|
|
Publication
|
|
|
|
London
:
Future medicine ltd
,
2018
|
|
|
ISSN
|
|
|
|
1479-6694
1744-8301
|
|
|
DOI
|
|
|
|
10.2217/FON-2018-0147
|
|
|
Volume/pages
|
|
|
|
14
:16
(2018)
, p. 1629-1645
|
|
|
ISI
|
|
|
|
000441782200010
|
|
|
Pubmed ID
|
|
|
|
29701076
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|